A recombinant viral haemorrhagic septicaemia virus glycoprotein expressed in insect cells induces protective immunity in rainbow trout by Lecocq-Xhonneux, F. et al.
Downloaded from www.microbiologyresearch.org by
IP:  193.191.134.1
On: Wed, 12 Oct 2016 10:12:18
Journal of General Virology (1994), 75, 1579-1587. Printed in Great Britain 1579 
A recombinant viral haemorrhagic septicaemia virus glycoprotein 
expressed in insect cells induces protective immunity in rainbow trout 
F. Lecocq-Xhonneux, 1. M.  Thiry, t I. Dheur, 1 M.  Rossius, t N. Vanderheijden, t J. Martial  2 
and P. de Kinkelin 3 
i EUROGENTEC s.a., Parc de recherche de la Cense Rouge, rue Bois Saint-Jean 14, 4102 Seraing, Belgium, 
~Laboratoire de Biologie Moldculaire et G~nie G~ndtique, Universit6 de Libge, 4000 Sart-Tilman, Belgium and 
3 Unitd de Virologie et Immunologie Molrculaires, lnstitut National de la Recherche Agronomique, 
78352 Jouy-en-Josas cedex, France 
Viral haemorrhagic septicaemia (VHS) is a fish rhabdo- 
virus infection of world-wide importance. Control 
policies have been established but the disease still causes 
heavy losses in fish farming. The development of a 
recombinant subunit vaccine was initiated to produce a 
safe and effective vaccine to protect fish against VHS. 
The VHS virus (VHSV) glycoprotein, which induces 
neutralizing antibodies in rainbow trout, was chosen for 
expression i insect cells using a baculovirus vector. The 
Mr of the recombinant protein estimated by SDS-PAGE 
I was slightly lower than that of the native viral protein. 
The recombinant protein displayed different degrees of 
glycosylation and was recognized in ELISA by neutral- 
izing antibodies. It was transported to the plasma 
membrane of insect cells where its ability to induce 
membrane fusion was preserved. The efficacy of the 
recombinant protein as a vaccine was compared with 
those of an inactivated and an attenuated vaccine. When 
injected intraperitoneally into rainbow trout, the baculo- 
virus-encoded protein was shown (i) to induce the 
synthesis of VHSV-neutralizing antibodies and (ii) to 
confer protection against virus challenge. Immunization 
performed by immersion failed. This is the first report of 
a recombinant vaccine that protects fish against VHSV. 
Introduction 
Viral haemorrhagic septicaemia (VHS) is a rhabdovirus 
infection of cold water fish such as rainbow trout 
(Oncorhynchus mykiss), brown trout (Salmo trutta), 
grayling (Thymallus thymallus), whitefish (Coregonus 
sp.), pike (Esox lucius) and turbot (Scophthalmus 
maximus). It is prevalent in continental Europe where it 
is a matter of concern because of its economic onse- 
quences to rainbow trout farming in both fresh and sea 
water. Recently VHS virus (VHSV) has spread to the 
North Western Pacific coast of America where rainbow 
trout (Brunson et al., 1989), chinook salmon (O. 
tshawytscha) (Hopper, 1989) and Pacific cod (Gadus 
macrocephalus) (Meyers et al., 1992) were found to be 
asymptomatic virus carriers. VHS is thus becoming a fish 
disease of world-wide importance. 
Until now, the spread of VHSV has been restricted 
through the establishment of a control policy. Most of 
the time, the results were rather poor, in so far as this 
method was applied to heavily infested zones where 
VHSV is harboured by farmed and wild fish. 
For over 10 years it has been established that fish that 
are naturally protected against overt VHS possess virus- 
neutralizing antibodies (NAb) (de Kinkelin et al., 1977). 
Thus immunoprophylaxis appeared to be a possible 
means of controlling VHS. Several vaccination studies 
were performed after the mid-1970s as previously 
reviewed (de Kinkelin, 1988). Briefly, effective anti-VHS 
protection could be obtained either by the injection of 
inactivated virus or by the water route delivery of 
attenuated virus variants (Jorgensen, 1976; de Kinkelin 
et al., 1980; de Kinkelin & Bearzotti-Le Berre, 1981). 
The former vaccine was safe but was not suitable for 
delivery to a large number of juvenile fish which are the 
main target of VHSV infection. The latter vaccines were 
easy to deliver but retained some degree of virulence 
which from a regulatory point of view prohibited their 
use, in as much as the mechanisms of attenuation were 
not clarified (Bernard et al., 1983, 1985). 
Recombinant subunit vaccine technology therefore 
appeared to be a suitable alternative for producing a safe 
and effective vaccine against VHS. It has been shown 
that the VHSV epitopes responsible for inducing pro- 
tection are located on the surface glycoprotein (G), as is 
the case for other rhabdoviruses (Wiktor et al., 1973; 
Kelley et al., 1972; Engelking & Leong, 1989a, b), and 
that antibodies to the G protein are able to abolish virus 
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infectivity (de Kinkelin et al., 1984; Lorenzen et al., 
1990). A cDNA copy of the mRNA coding for G protein 
of VHSV has been cloned (Thiry et al., 1990) and 
sequenced (Thiry et al., 1991). The VHSV G protein was 
also expressed in Escherichia coli, as a fusion protein 
with the bacterial enzyme TrpE but this protein failed to 
induce either consistent protection or the synthesis of 
neutralizing antibodies whatever the route of delivery 
(unpublished results). 
Prior to and in parallel with the above work, other 
investigations were carried out on the molecular biology 
of infectious haematopoietic necrosis virus (IHNV) 
(Koener et al., 1987), gnother fish rhabdovirus, which is 
the causative agent of a severe systemic infection of 
salmonid fish species that resembles VHS clinically. IHN 
was originally found in the North Pacific Ring but has 
recently spread to Continental Europe (Hattenberger- 
Baudouy et al., 1989). These experiments led to the 
construction of a recombinant vaccine in which a 
fragment of the G protein of IHNV was fused with the 
E. coli enzyme TrpE (Gilmore et al., 1988). Fingerling 
trout immunized by immersion in crude bacterial extract 
were protected against virus challenge. More recently, 
the immunodominant domain of the IHNV glycoprotein 
has been localized to the carboxy-terminal region (Xu et 
al., 1991). 
Concerning VHS, it was demonstrated very recently 
(Lorenzen et al., 1993) that the injection of rainbow trout 
with an almost complete VHSV G protein produced in 
E. coli could elicit specific anti-G antibodies. The 
recombinant protein had to be carefully renatured before 
injection. The serum of some of the immunized fish 
possessed a heat-labile neutralizing activity against 
VHSV. 
In contrast with the previous findings, our negative 
results with the recombinant G protein of VHSV 
produced in E. coli prompted us to shift from expression 
in bacteria to expression in eukaryotic ells, a system 
more likely to result in a properly glycosylated protein. 
According to the existing evidence from other animal 
rhabdovirus research the glycosylation of G protein is 
likely to be crucial for the induction of a neutralizing 
antibody response (Gibson et al., 1981; Machamer & 
Rose, 1988; Prehaud et al., 1989). 
The present paper describes how the cDNA of the 
gene of VHSV G protein was cloned in a baculovirus 
vector (Luckow & Summers, 1988) which mediated a
high level of expression. The potency of the recombinant 
vaccine was compared with those of a live-attenuated 
vaccine and an inactivated virus vaccine. When injected 
into rainbow trout, the baculovirus-encoded protein was 
shown (i) to induce the synthesis of VHSV-neutralizing 
antibodies and (ii) to confer protection against virus 
challenge. 
Methods 
Virus and cells. Autographa californica nuclear polyhedrosis virus 
(AeNPV) and recombinant baculovirus stocks were grown and assayed 
in confluent monolayers or suspensions of Spodopterafrugiperda cells 
(Sf9) in Ex-Cell 400 medium (JRH Biosciences) according to the 
procedures described by Summers & Smith (1988). 
The epithelioma papulosum cyprini (EPC) cell line (Fijan et al., 
1983) was grown at 30 °C in Stoker's medium (Gibco BRL) buffered 
with 0-16 M-Tris-HC1 at pH 7.4 and supplemented with 10 % fetal calf 
serum (FCS), 10% tryptose phosphate and antibiotics. For virus 
production, the pH was adjusted to 7'6 and the FCS content was 
reduced to 2 %. 
VHSV 07.71, a French isolate from rainbow trout, belonging to 
serotype 1, was propagated in EPC cells at 15 °C as previously 
described (Fijan et al., 1983) whereas 07(25)111, an attenuated variant 
of 07.71 (Bernard et al., 1985) was propagated at 22 °C. 
Inactivated VHSV vaccine was prepared by u.v. irradiation of a 
suspension of 50 Ixg/ml purified 07.71 virus with an over-killing factor 
of 10. Virus was purified by sucrose gradient centrifugation according 
to de Kinkelin (1972). 
Construction of  AcNPV recombinant transfer vector. DNA manipu- 
lations were carried out essentially following the procedures described 
by Sambrook et aL (1989). The transfer vector pJVP10Z (Vialard et al., 
1990), kindly provided by Dr C. D. Richardson (Biotechnology 
Research Institute, National Research Council, Montreal, Canada), 
containing the polyhedrin gene and the E. coli fl-galactosidase g ne was 
digested with NheI prior to insertion of the G gene of VHSV isolate 
07.71 under the control of the AcNPV polyhedrin promoter. The 
VHSV G gene was synthesized by PCR, according to Saiki et al. (1988), 
from plasmid pSHVG1 (Thiry et at., 1991). The following amplimers 
were used in order to introduce NheI sites near the initiator codon and 
stop codon: 5' GG GCT AGC ATG GAA TGG AAC ACT 3' 5' 
GG GCT AGC TCA GAC CGT CTG ACT 3'. The correct orien- 
tation of the G protein coding region in the derived recombinant 
transfer vector, pBacSHVG, was verified by restriction endonuclease 
mapping. 
Transfection and selection of  recombinant viruses. Sf9 cells were 
transfected with a mixture of the recombinant plasmid pBacSHVG 
(10 I~g) and wild-type AcNPV DNA (1 ~tg) by calcium phosphate 
precipitation. Recombinant viruses were selected following three 
rounds of purification of plaques that were polyhedron-negative and 
stained blue as described by Summers & Smith (1988). 
Recombinantglycoproteinproduction. Sf9 cell suspensions in exponen- 
tial growth phase were infected, according to the procedures described 
by Summers & Smith (1988), by selected recombinant baculovirus at an 
m.o.i, of 1. The ceils were harvested 4 days post-infection by 
centrifugation and cell pellets were stored at -70  °C until use. 
Negative controls were prepared in the same manner with wild-type 
baculovirus or uninfected S19 cells. 
Immunoblotting. The VHSV G protein-specific monoclonal ntibody 
(MAb) used (A17) was isolated by Bearzotti & de Kinkelin (1987) and 
purchased from Sanofi Aquatic Animal Health. Immunoblot analyses 
were carried out under denaturing conditions. Samples for SDS-PAGE 
were boiled for 5 min in dissociation buffer containing 2% SDS and 
5 % 2-mercaptoethanol, subjected to electrophoresis (Laemmli, 1970) 
and electrotransferred to PVDF membrane (Immobilon; Millipore). 
The blot was incubated for 1 h at 37 °C or overnight at 4 °C with 
blocking solution (5 % non-fat dried milk in 10 mM-PBS pH 7.3), then 
transferred toa blocking solution containing 5 ~tg/ml of MAb A 17 and 
incubated for 3 h at 37 °C. After several washes, bound antibodies were 
detected with a peroxidase-conjugated anti-mouse immunoglobulin 
(Gamma). The horseradish peroxidase colour development reagent 
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from Bio-Rad Laboratories was used as chromogenic substrate for 
peroxidase activity detection. 
Deglyeosylation assay. Proteins were denatured for 5 rain at 100 °C 
with 1% SDS and 0"5% 2-mercaptoethanol before being diluted 
tenfold in PBS containing 20mM-EDTA and 0.6% Triton X-100. 
Samples were incubated for 18 h at 37 °C with 5 U/ml of a mixed 
endoglycosidase F/N-glycosidase F preparation (Boehringer Mann- 
heim) and analysed by immunoblotting asdescribed above. 
ELISA. Microtitre wells (Nunc; Immunoplate Maxisorp) were 
coated by incubation overnight at 4 °C with 100 ~tl of MAb A17 diluted 
to 21ag/ml in carbonate buffer pH9.6 (15mM-Na2CO 3, 35mM- 
NaHCO3, 0-2 g/1 NAN3). After repeated washing with PBS containing 
0.1% Tween 20 (PBS-T), remaining sites were blocked by incubation 
with 1% BSA in PBS-T for 45 min at 37 °C. Twofold serial dilutions 
of antigen (50 lal/well) were then incubated for 3 h at 37 °C in blocking 
solution with 50 lal of peroxidase-conjugated MAb L7 (Sanofi Aquatic 
Animal Health) according to Mourton et al. (1990). MAbs L7 and A17 
are both VHSV G protein-specific but L7 is able to neutralize VHSV in 
vitro whereas A17 is not (Bearzotti & de Kinkelin, 1987). 
For antigen preparation, insect cells (107 cells/ml) and purified virus 
(5 lag/ml) were disrupted in PBS with 50 mM-octyl-glucopyrauoside 
(OG; Boehringer Mannheim) and incubated for 30 min on ice before 
assay. An anti-protease mixture (1 mM-EDTA, 1 mM-PMSF, 0-5 I~g/ml 
leupeptin and 0"7 ~tg/ml pepstatin; Boehringer Mannheim) was also 
added. 
The chromogenic substrate for peroxidase, o-phenylenediamine 
dihydrochloride (Sigma) was used in appropriate buffer (66.7 mM- 
Na2HPO 4, 34.7 raM-citric acid pH 4.5) at a concentration of 1 mg/ml 
with 1 lal/ml of 30 % H20 ~. The reaction was stopped after 15 min with 
50 lal per well of 4 M-H2SO a and the Aa92 determined. 
This assay allowed the determination of the approximate con- 
centration of the G protein in samples intended for administration to
fish. ELISA values generated by a known quantity of purified viral 
proteins were compared with those of lysed recombinant baculovirus- 
infected insect cells in the linear part of the curves. G protein was 
considered to accotmt for 16% of total viral protein according to de 
Kinkelin et al. (1980). 
Rainbow trout fry immunization trials 
In the first series of trials, the immunity raised in trout by our 
recombinant vaccine was compared with that induced by inactivated 
VHSV and attenuated VHSV, both acting as positive vaccine controls. 
A second series of trials was designed to check the reliability of 
protection due to injection of the recombinant vaccine and the 
effectiveness of its water-route delivery. The trials on animals were 
performed at 10 to 11 °C in a contained laboratory and the effluent 
water was sterilized by chlorination. 
(i) First series of trials. Virus-free fry from the INRA's strain of 
rainbow trout (an extensively cross-bred population representative of 
French strains of rainbow trout), 1400 degree days old and weighing 2
to 3 g, were used. Each fish immunized with the recombinant vaccine 
received 1 x 105 baculovirus-infected Sf9 cells in PBS via an intra- 
peritoneal (i.p.) injection whereas the fish from the control group 
received the same dose of Sf9 cells alone. The fish immunized with 
inactivated virus were injected i.p. with 160 ng virus in PBS and the 
controls with PBS only. All injected products were mixed 1 : 1 (v/v) 
with Suvaxyn, an oil-in-water emulsion used as an adjuvant, kindly 
provided by Dr L. Hilgers (Solvay Duphar Animal Health). Lastly, the 
attenuated virus was administered by immersion of the fish in water 
containing 5x 105 p.f.u, virus/ml for 25 min, with bubbling air. The 
fish in the control group were similarly immersed in an aqueous 
suspension of disrupted EPC cells (105 cells/ml). 
Forty-nine days post-immunization, 10 fish/group were bled after 
severing the caudal peduncle. Blood samples (50 ~tl) were immediately 
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diluted 1 : 10 in sterile PBS and stored at 4 °C for 16 h before further 
processing. Following blood sampling, each group of fish was divided 
into two smaller groups of approximately equal size and waterborne 
challenge was performed by immersing the fish for 3 h in a static 
aqueous suspension of VHSV isolate 07.71 at a concentration of 
5 x 104 p.f.u./ml. The mortality in these groups was recorded aily for 
30 days post-challenge and the diagnosis of VHS was made on the basis 
of clinical signs of disease or in the case of asymptomatic infection, by 
virological examination. 
Statistics were calculated according to the Z 2 table with the Yates 
correction (Table 1). The relative percentage survival (RPS; Johnson et 
al., 1982) was also determined by the formula RPS = [1 - (% loss of 
immunized fish/% loss of controls)] x 100. 
(ii) Second series of trials. This series of trials was conducted from 
mid-September to mid-November using 1000 degree days old fish from 
the INRA's spring spawning trout strain (mean weight 1.8 g). The 
recombinant vaccine was either injected as in the first series or 
administered byimmersion. In the latter instance 50 fish were immersed 
for 15 min with bubbling air in 200 ml of an aqueous uspension of 
4 x 107 recombinant baculovirus-infected c lls disrupted by one freezing 
and thawing cycle. The mock-immunized group was similarly treated 
with a suspension of Sf9 cells. The immunization trial and challenge 
were the same as for the first series (Table 1). 
Serum neutralization test (SNT). The SNT in the presence of trout 
complement (Dorson & Torchy, 1979) was performed by plaque assay 
in microplates (Olesen & Jorgensen, 1986) using 07.71 as the viral 
antigen. For that purpose, the clotted, PBS-diluted blood samples were 
centrifuged for 20 min at 2000 g at 4 °C and the supernatants were 
collected, heated at 45 °C for 30 min and cooled to 4 °C. SNTs were 
conducted with twofold serial dilutions of sera from 1/50 to 1/400 
resulting from the mixing (v/v) of 25 ~tl of sera diluted 1/25 to 1/200 
with 25 ~tl of virus suspension containing 6x 103p.f.u./ml and 
containing trout complement. Incubation was performed at 4 °C 
overnight and the plaque assay was performed by inoculating EPC cell 
monolayers grown in 96-well culture plates with 10 ktl of each 
virus-serum ixture (two wells/dilution). After 1 h of incubation at 
15 °C, 60 lal/well of Stoker's medium with carboxymethylcellulose was
added and plates were incubated for 72 h at 15 °C. The infected 
monolayers were then fixed and stained with 0-5 % crystal violet in 
10% formalin, microplaques were counted and the neutralizing 
antibody titre was determined as the reciprocal value of the highest 
serum dilution causing 50% reduction of the average number of 
plaques counted in negative control cultures with normal trout serum. 
Each microplate ncompassed 10 assays plus one positive and one 
negative control serum. 
Results 
Recombinant  glycoprotein expression 
Sf9 cells were in fected w i th  the w i ld - type  and  the  
recombinant  bacu lov i rus  and  ana lysed  by  immuno-  
b lo t t ing  since the recombinant  G prote in  was  masked for  
the  most  par t  by  insect  cell p ro te ins  in Coomass ie  b lue-  
s ta ined  gels (not  shown) .  Us ing  the VHSV (3 prote in -  
specif ic MAb A17,  several  bands  cor respond ing  to Mrs  
rang ing  f rom 52K to 63K were revea led  on ly  in 
recombinant  v i rus - in fec ted  cells (Fig.  1, lane 4). The  
g lycoprote in  expressed  in insect  cells exh ib i ted  a lower  
M r in SDS-PAGE than  d id  the nat ive  (3 prote in  s ince 
the M r o f  the  (3 o f  pur i f ied  VHSV was about  66K ( lane 
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1 2 3 4 5 6 7 
- 200K 
- 97K 
- -  68K 
- -  43K 
- 29K 
Fig. 1. Characterization of baculovirus-expressed VHSV G protein in 
immunoblotting by MAb to G protein. Lane 1, purified VHSV 
particles (1 lag); lane 2, deglycosylated purified VHSV (0'1 lag); lane 3, 
deglycosylated recombinant baculovirus-derived G protein (104 in- 
fected Sf9 cells); lane 4, recombinant baculovirus-infected Sf9 cells 
(5 x 10 a cells); lane 5, wild-type baculovirus-infected Sf9 cells (5 x 104); 
lane 6, uninfected Sf9 cells (5 x 104); lane 7, prestained M r markers 
(Gibco BRL). 
1). After deglycosylation with endoglycosidase F and N- 
glycosidase F, the native and recombinant G proteins 
showed the same relative mobility in the gel (lanes 2 and 
3). The different bands present in the infected cells 
suggest different levels of glycosylation. Their relative 
intensity varied during the course of infection to the 
detriment of the highly glycosylated form (data not 
shown). The level of expression i creased further after 4 
days post-infection but infected cells began to disrupt. 
ELISA 
As expected, G-specific MAbs did not react with wild- 
type baculovirus-infected cells, but recombinant samples 
were recognized by L7 MAb (Fig. 2). Saturation or steric 
hindrance probably interfered in the first dilutions. 
Another anti-G neutralizing MAb, C10 (Bearzotti & de 
Kinkelin, 1987), was also shown to bind to the 
recombinant protein (data not shown). 
As shown in Fig. 2, l0 s cells were estimated to contain 
approximately 32 ng of recombinant G protein. Indeed, 
3.1 x 104 recombinant infected cells produced the same 
signal as 63 ng of purified virus (approximately 10 ng of 
G protein). Similar values were obtained for different 
preparations of the recombinant G protein. 
Total cell lysates, prepared by OG treatment, were 
compared by ELISA with the supernatants of a 100 000 g 
centrifugation of the same extracts. Similar A492 values 
were obtained for both samples (data not shown). This 
assay therefore detected only the soluble fraction of the 
recombinant proteins. ELISA was not performed on the 
insoluble pellet. 
The same samples were then analysed by immuno- 
blotting (data not shown). In this case, the response of 
Purified VHSV (ng) 
500 250 125 63 31 16 8 4 
3.0 I I i I i 
2-5 
2-0 




0c c~ o ~ Q i 
10 5 2.5 1.25 0.63 0.31 0-16 0-0~ 
Number of infected Sf9 cells (× 10 -5) 
Fig. 2. Characterization of baculovirus-expressed VHSV G protein in 
ELISA with anti-G protein MAb. Symbols: purified VHSV (I-q); Sf9 
cells infected with wild-type baculovirus (©); S19 cells infected with 
VHSV G recombinant baculovirus (Q). 
the total cell lysate was higher than that of the 100000 g
supernatant, suggesting that SDS and 2-mercaptoethanol 
treatment solubilized the recombinant G protein more 
efficiently than OG treatment. 
If OG treatment did not solubilize all the synthesized 
recombinant glycoproteins and the ELISA recognized 
only the soluble fraction of these, the value of 32 ng G 
protein per 105 Sf9 cells was probably an underestimate. 
However, this assay allowed the estimation of the 
minimum quantity of correctly folded G protein that was 
administered to fish and allowed the comparison of 
several vaccine preparations. 
Fusion activity 
When Sf9 cells were infected with the recombinant 
baculovirus, multinucleate syncytia spontaneously ap- 
peared from 48 h post-infection (Fig. 3). This was never 
observed with wild-type virus or mock-infected cells. The 
pH of the Ex-Cell 400 medium was 6.3 during the 
infection course and fusion was inhibited when the pH of 
the culture medium was adjusted to greater than 6"6 (not 
shown). Syncytia were more readily observed on mono- 
layers than in suspension culture. 
Immunization trials 
Vaccination with attenuated VHSV caused the death of 
13 fish. VHSV multiplication could be shown in nine of 
these fish. The administration of the different products, 
and especially that of the recombinant vaccine, was safe 
(Table 1). The delivery of this vaccine by i.p. injection 
was followed by the production of neutralizing anti- 
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Fig. 3. Micrographs ofSf9 cell monolayers 5 days post-infection. Cells 
were mock-infected (a)or infected at an m.o.i, of 10 with wild-type 
baculovirus (b) or VHSV G recombinant baculovirus (c). Arrowheads 
indicate polyhedrin occlusions inwild-type baculovirus-infected ells. 
bodies in fish. Four fish out of 10 responded in the first 
series of trials, three of them exhibited a neutralizing titre 
of 50 and one a titre of 100. Similarly in the second series 
of trials, two out of 10 fish reacted positively at a titre of 
200. Conversely none of the mock-vaccinated fish 
possessed neutralizing antibodies in either series of trials. 
The fish in the positive control groups (10 fish in each 
group), vaccinated with inactivated or attenuated vac- 
cines, gave five (four at 50, one at 100) and three (50, 100, 
400) positive sera respectively. The negative controls, 
mock-vaccinated bybath or injection, remained negative. 
During virus challenge in the first series of trials, the 
clinical signs followed the classical course of VHS 
disease. Depending on the group, the mortality occurred 
between day 5 and 7 post-infection; after this time 
haemorrhage and oedema were readily observed with 
exophthalmia nd melanosis. Nervous form of the 
disease appeared by day 24. Table 1 gives the survival 
values of the duplicate experiments. There is good 
agreement between duplicate values. The percentage 
survival for the recombinant, inactivated and attenuated 
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Table 1. Results of immun&ation trials of rainbow trout fry against VHS with vaccine 
preparations of recombinant baculovirus, inactivated VHSV and attenuated VHSV 
Fish Positive Fish Challenge Survival 
Series Experimental group immunized SNT* challenged survivors (%) ;(2 RPS 
1 Recombinant vaccine 105 4/10 46+47 31 +33 68-8 4.2 33.9 
(injection) P < 0"05 
1 Control 105 0/10 44+45 22+25 52.8 
(injection) 
1 Inactivated vaccine 103 5/10 45+45 30+33 70 25.7 56.5 
(injection) P < 0-005 
1 Control 103 0/10 45+45 13+15 31.1 
(injection) 
1 Attenuated vaccine 93 3/10 40 + 40 32 + 26 72'5 22.3 57.6 
(bath) P < 0"005 
1 Control 101 0/10 46+45 17+ 15 35.2 
(bath) 
2 Recombinant vaccine 94 2/10 42+42 39+41 95.2 11.8 80.2 
(injection) P < 0-005 
2 Control 110 0/10 49 + 50 36 + 39 75.8 
(injection) 
2 Recombinant vaccine 50 NDt 48 28 58"3 0'001 --4"3 
(bath) P > 0" 1 
2 Control 50 NO 50 30 60 
(bath) 
* Number of sacrificed fish out of 10, responding in the seroneutralization test at titres ~> 50. 
t NO, Not done. 
vaccine groups and their controls were 68"8, 52.8; 70, 
31-1; and 72.5, 35.2, respectively. According to the Z 2 
analysis, the differences in the mortalities of vaccinated 
and non-vaccinated groups were statistically significant 
(e < 0.05). 
In the second series of trials (Table 1), the course of 
immunization and virus challenge was similar overall to 
that recorded in the first series but the mortality rates 
remained moderate as we observed frequently with 
challenges performed in the autumn. They finally resulted 
in 95.2 % survival in the group of fish injected with the 
recombinant vaccine and 75"8 % in the mock-vaccinated 
fish group. In contrast no significant difference in survival 
between water route recombinant vaccine-treated and 
mock-treated fish was found. 
Discussion 
The M r of the recombinant VHSV G protein expressed 
in insect cells never reached that of the natural viral G 
protein. It displayed a range of Mrs corresponding to 
different degrees of glycosylation (Fig. 1). Such differ- 
ences in electrophoretic mobility have been observed 
with other recombinant viral glycoproteins expressed in 
insect cells (Prehaud et al., 1989; Bailey et al., 1989; 
Kuroda et al., 1990; Matsuura et al., 1992; Tuchiya et 
al., 1992). They appear to be due to differences in the 
complexities and types of glycan attached to proteins 
made in the different cell types. Sf9 cells have the 
capacity to trim N-glycans to trimannosyl cores and to 
process these further by the addition of fucose (Kuroda 
et al., 1990), but they are known to lack sialyl transferase 
activities (Prehaud et al., 1989). 
Correct glycosylation is known to influence protein 
folding. Carbohydrate chains protect he G protein of 
vesicular stomatitis virus (VSV) from forming aberrant 
interchain disulphide bonds (Machamer & Rose, 1988). 
The size of oligosaccharides present can be crucial for 
attaining the proper conformation (Gibson et al., 1981). 
But in spite of differences in glycosylation, the recombi- 
nant VHSV G protein seemed to be correctly folded 
since the presence of neutralizing epitopes could be 
detected by ELISA with neutralizing monoclonal anti- 
bodies L7 and C10. Both antibodies are known to confer 
passive protection of rainbow trout against VHSV 
challenge (P. de Kinkelin & F. Lecocq-Xhonneux, un- 
published results). 
Formation of syncytia with cells infected by VHSV G 
recombinant baculovirus proved that the recombinant 
protein was anchored in the plasma membrane. Immuno- 
fluorescence analysis on intact cells confirmed the 
location of the glycoprotein on the cell surface (data not 
shown). The formation of syncytia was also observed 
when St9 cells expressed VSV G protein (Bailey et al., 
1989) and rabies virus G protein (Tuchiya et al., 1992). 
The fusion was shown to be pH-dependent and was 
inhibited when the pH of the medium exceeded 6.2 and 
6.0 respectively. Recombinant VHSV G thus seemed to 
induce membrane fusion at a slightly higher pH than the 
other rhabdoviral glycoproteins. 
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Fig. 4. Survival rate of fish challenged with VHSV. First series of trials: fish were immunized 49 days before challenge, ither by i.p. 
injection with recombinant baculovirus-infected Sf9 cells (C)), mock-infected Sf9 cells (O), inactivated VHSV (I--1) or PBS (11), or by 
balneation with attenuated VHSV (A) or disrupted EPC ceils (A). Second series of trials: fish were injected i.p. with recombinant 
baculovirus-infected ells ((3) or mock-infected Sf9 cells (O), or immersed with the same products (©, O) respectively. Points have 
been plotted as an average of the duplicates. 
The protein was transported to the cell surface in a 
functional conformation since it could mediate the fusion 
of the cellular membranes at low pH. Indeed, the 
glycoproteins of rhabdoviruses are known to trigger 
fusion between the viral envelope and the membrane of 
the endocytosis vesicles at low pH, leading to the transfer 
of the viral ribonucleoprotein into the cytoplasm (Matlin 
et al., 1982; Superti et al., 1984). The low pH allows these 
proteins to adopt a different conformation probably 
leading to the exposure of hydrophobic regions at the 
protein surface and thus allowing membrane fusion 
(Crimmins et al., 1983; Gaudin et al., 1991). 
All these results suggested that the VHSV G protein 
expressed in insect cells was a good candidate for 
vaccination trials. Nevertheless, only a fraction of the 
synthesized G protein seemed to be correctly processed 
and exported to the cell surface. Only a small amount of 
VHSV recombinant glycoprotein could be solubilized in 
non-ionic detergents such as Triton X-100, CHAPS or 
OG (data not shown). The bulk of the protein was 
probably in an aggregated form within intracellular 
membranes or associated with cellular proteins. This is in 
agreement with cytoplasmic inclusions een by immuno- 
fluorescence (data not shown). 
Even though the degree of protection is rather low, the 
i.p. injection of the baculovirus-encoded recombinant 
VHSV G protein provided the same level of protection 
against challenge as the classical vaccines (Fig. 4). This is 
the first report of protection against this viral disease 
provided by a recombinant antigen. 
The protective response was accompanied by the 
synthesis of neutralizing antibodies. These were not heat- 
labile since they were resistant to the decomplementation 
procedure (30 min at 45 °C). Nevertheless, ome of the 
sera tested were negative in SNT. They were probably 
below the threshold of sensitivity or came from fish that 
did not respond to the vaccination. This variability in 
SNT response is recognized (de Kinkelin et al., 1984; 
Olesen et aL, 1991). 
Not all the vaccinated fish were protected against 
challenge with VHSV but the survival rates were 
significantly higher than in mock-immunized controls. 
The two immunization trials showed differences in 
survival rates with the same antigen (68"8 % and 95.2 %, 
52.8% and 75"8%; Table 1). Differences in mortality 
were often observed either between different batches of 
fish or depending on the season at which the challenge 
was performed. We have observed over many years that 
mortality can vary between 20 and 95 %. This results in 
significant variability of the RPS factor. It thus seems 
inappropriate to evaluate the efficacy of vaccines on the 
basis of this ratio alone. In this work, the RPS provided 
by the recombinant vaccine was shown to vary from 33"9 
to 80.2 % depending on the experiment (Table 1). 
Differences in survival rates between vaccinated and 
non-vaccinated groups were higher for classical vaccines 
than for the recombinant one. The i.p. administration of
non-infected Sf9 cells induced some protective response 
but no NAb synthesis. In previous experiments, it was 
also observed that the injection of E. coli or yeast crude 
extracts could provide a limited but significant level of 
protection against he VHSV challenge in the absence of 
neutralizing antibodies (unpublished results). Similarly, 
injection of fish with PBS or the supernatant from 
bacterial cultures was shown to increase the level of 
natural antibodies (Michel et al., 1990), and it was also 
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demonstrated that such antibodies could interfere in vitro 
with virus multiplication (Gonzales et al., 1989). It thus 
seems possible that these antibodies might play a role in 
the resistance to viral infection. Moreover, we cannot 
exclude an effect of  the Suvaxyn adjuvant, although this 
oil-in-water emulsion would act rather as a carrier of  
antigen than as an immunostimulating adjuvant. 
Nevertheless, the immunogenicity of  the recombinant 
vaccine was demonstrated and in the first series the 
survival rate of  vaccinated fish (68"8%) was clearly 
higher than that of  controls (52.8%). To assess the 
efficacy of  the vaccine, its effects should be compared 
with untreated controls. Since these controls are lacking 
from this set of  trials, the survival rate of  the control set 
of  immersed fish (35"2 %) would probably be the more 
suitable for this comparison. In this case, the Z 2 value 
would reach 19.6 (P < 0"005) and the RPS factor 51.8. 
The recombinant vaccine was effective by i.p. injection. 
This administration route guaranteed that a known dose 
of  vaccine had been delivered to the fish. A 10-fold 
dilution of  the recombinant vaccine failed to protect fish 
(data not shown). A more practical administration 
method, immersion, was tested and neither NAb syn- 
thesis nor  protection was obtained. A possible ex- 
planation could be that the product did not penetrate 
into the fish. Indeed, the disruption of  infected cells by 
one freeze-thaw cycle released large aggregates probably 
unable to migrate through the epithelia of  the fish body 
surface. Moreover the concentration of  antigen was low 
(< 100 ng/ml)  as compared with the successful IHNV 
bath vaccination (Gilmore et al., 1988). In this case, 
the concentration of  the IHNV G protein was estimated 
to be greater than 100 ixg/ml. 
A recent vaccination assay per os was performed (data 
not shown) but failed in NAb synthesis and protective 
response as was previously found to be the case for 
inactivated and attenuated vaccines administered via this 
route. 
The recombinant VHSV G protein expressed in Sf9 
cells was recognized by anti-G neutralizing MAbs and 
was transported to the cytoplasmic membrane surface 
where the fusogenic activity was preserved. In immuni- 
zation trials, the recombinant protein could induce NAb 
synthesis and protection in rainbow trout when admin- 
istered by the i.p. route, but failed by more practical 
administration methods like balneation and per os. 
Nevertheless, this is the first report of  a recombinant 
vaccine against VHSV and the potential commercial 
future of  this product is in the process of  being studied. 
This work was supported by the Community Research Programme 
in the Fisheries Sector (FAR; project no. AQ. 1.260). 
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